Synonym
PD 154075; PD154075; PD-154075; CI-1021; CI1021; CI 1021
IUPAC/Chemical Name
Carbamic acid, N-((1R)-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-(((1S)-1-phenylethyl)amino)ethyl)-, 2-benzofuranylmethyl ester
InChi Key
IVIQHHCTWSXXCT-WENCNXQZSA-N
InChi Code
InChI=1S/C30H29N3O4/c1-20(21-10-4-3-5-11-21)32-28(34)30(2,17-23-18-31-26-14-8-7-13-25(23)26)33-29(35)36-19-24-16-22-12-6-9-15-27(22)37-24/h3-16,18,20,31H,17,19H2,1-2H3,(H,32,34)(H,33,35)/t20-,30+/m0/s1
SMILES Code
O=C(OCC1=CC2=CC=CC=C2O1)N[C@](C)(CC3=CNC4=C3C=CC=C4)C(N[C@H](C5=CC=CC=C5)C)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
495.58
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Singh L, Field MJ, Hughes J, Kuo BS, Suman-Chauhan N, Tuladhar BR, Wright DS, Naylor RJ. The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin- induced delayed emesis in the ferret. Eur J Pharmacol. 1997 Feb 26;321(2):209-16. doi: 10.1016/s0014-2999(96)00950-8. PMID: 9063690.
2: Gonzalez MI, Field MJ, Holloman EF, Hughes J, Oles RJ, Singh L. Evaluation of PD 154075, a tachykinin NK1 receptor antagonist, in a rat model of postoperative pain. Eur J Pharmacol. 1998 Mar 5;344(2-3):115-20. doi: 10.1016/s0014-2999(97)01581-1. PMID: 9600644.
3: Horwell D, Pritchard M, Raphy J, Ratcliffe G. 'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors. Immunopharmacology. 1996 Jun;33(1-3):68-72. doi: 10.1016/0162-3109(96)00058-6. PMID: 8856117.
4: Boyle S, Guard S, Higginbottom M, Horwell DC, Howson W, McKnight AT, Martin K, Pritchard MC, O'Toole J, Raphy J, et al. Rational design of high affinity tachykinin NK1 receptor antagonists. Bioorg Med Chem. 1994 May;2(5):357-70. doi: 10.1016/s0968-0896(00)82192-6. PMID: 7922147.
5: Zhu Z, Chen HG, Goel OP, Chan OH, Stilgenbauer LA, Stewart BH. Phosphate prodrugs of PD154075. Bioorg Med Chem Lett. 2000 May 15;10(10):1121-4. doi: 10.1016/s0960-894x(00)00183-9. PMID: 10843232.